From the Medical Surgical Critical Care Unit, Centre Hospitalier René Dubos, Pontoise, France.
ASAIO J. 2020 Mar;66(3):239-246. doi: 10.1097/MAT.0000000000000974.
Venovenous and venoarterial extracorporeal membrane oxygenation (ECMO) are lifesaving supports that are more and more frequently used in critically ill patients. Despite of major technological improvements observed during the last 20 years, ECMO-associated hemolysis is still a complication that may arise during such therapy. Hemolysis severity, directly appreciated by plasma free hemoglobin concentration, may be present with various intensity, from a nonalarming and tolerable hemolysis to a highly toxic one. Here, we propose a review dedicated to extracorporeal membrane oxygenation (ECMO)-associated hemolysis, with a particular emphasis on pathophysiology, prevalence, and clinical consequences of such complication. We also focus on laboratory assessment of hemolysis and on the limits that have to be known by clinicians to prevent and manage hemolytic events.
静脉-静脉和静脉-动脉体外膜肺氧合(ECMO)是一种救命支持,越来越多地用于危重病患者。尽管在过去 20 年中观察到了重大的技术进步,但 ECMO 相关的溶血仍然是这种治疗中可能出现的并发症。溶血的严重程度,直接通过血浆游离血红蛋白浓度来评估,可以从非警报和可耐受的溶血到高度毒性的溶血,其严重程度各不相同。在这里,我们提出了一篇专门针对体外膜肺氧合(ECMO)相关溶血的综述,特别强调了这种并发症的病理生理学、患病率和临床后果。我们还重点介绍了对溶血的实验室评估,以及临床医生必须了解的限制,以预防和处理溶血事件。